Literature DB >> 24269583

Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy.

Atsutaka Noguchi1, Toru Kaneko2, Keiko Naitoh2, Masashi Saito2, Kazuro Iwai2, Ryuji Maekawa3, Takashi Kamigaki2, Shigenori Goto4.   

Abstract

Recent progress has been made in understanding the mechanisms of antitumor immune responses, which may further clarify the immune status of cancer patients. In this study, we performed a detailed evaluation of the immunological status of 47 patients with advanced solid cancer, who had received no immunosuppressive treatment, and compared the results with 32 healthy subjects. Flow-cytometry data for peripheral blood were obtained using 19 monoclonal antibodies against various cell surface and intracellular molecules. Absolute numbers of T cells, several T cell subsets, B cells, and NK cells were significantly decreased in patients compared with healthy subjects. The percentage of CD27(+)CD45RA(+) T cells was lower and that of CD27(-)CD45RA(-) T cells was higher in patients compared with controls. Regulatory and type 2 helper T cells were elevated in patients relative to healthy subjects. The percentage of perforin(+) NK cells was significantly lower in patients than in controls. These results suggest a dysfunctional anti-tumor immune response in cancer patients. Furthermore, peripheral blood from 26 of 47 cancer patients was analyzed after adoptive T cell immunotherapy (ATI). ATI increased the number of T cell subsets, but not B and NK cells. The number and percentage of regulatory T cells decreased significantly. These results suggest that ATI can restore impaired and imbalanced T cell immune status.
Copyright © 2013 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adoptive immunotherapy; Flow cytometry; Immunological status; T cell

Mesh:

Substances:

Year:  2013        PMID: 24269583     DOI: 10.1016/j.intimp.2013.11.009

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  10 in total

Review 1.  ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW.

Authors:  Yuya Yoshimoto; Koji Kono; Yoshiyuki Suzuki
Journal:  Fukushima J Med Sci       Date:  2015-07-02

2.  Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model.

Authors:  Jan Aleksander Kraśko; Karolina Žilionytė; Adas Darinskas; Neringa Dobrovolskienė; Agata Mlynska; Svetlana Riabceva; Iosif Zalutsky; Marina Derevyanko; Vladimir Kulchitsky; Olga Karaman; Natalia Fedosova; Tatiana Vasyliyvna Symchych; Gennady Didenko; Vasyl Chekhun; Marius Strioga; Vita Pašukonienė
Journal:  Oncol Lett       Date:  2018-02-05       Impact factor: 2.967

3.  Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer.

Authors:  Miyabi Miura; Eishiro Mizukoshi; Tomomi Hashiba; Masaaki Kitahara; Tomoharu Miyashita; Takafumi Mochizuki; Shigenori Goto; Takashi Kamigaki; Rishu Takimoto; Taro Yamashita; Yoshio Sakai; Tatsuya Yamashita; Masao Honda; Shuichi Kaneko
Journal:  Cancer Med       Date:  2020-06-11       Impact factor: 4.452

4.  A case of a patient receiving combination therapy with paclitaxel plus bevacizumab and adoptive activated αβ T-cell immunotherapy in advanced breast cancer.

Authors:  Takaaki Masuda; Atsushi Nonami; Fumiaki Tanaka; Yuki Ando; Masatoshi Eto; Koshi Mimori
Journal:  Breast J       Date:  2020-12-05       Impact factor: 2.431

Review 5.  Overview of Epstein-Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic Options.

Authors:  Valli De Re; Giulia Brisotto; Ombretta Repetto; Mariangela De Zorzi; Laura Caggiari; Stefania Zanussi; Lara Alessandrini; Vincenzo Canzonieri; Gianmaria Miolo; Fabio Puglisi; Claudio Belluco; Agostino Steffan; Renato Cannizzaro
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

Review 6.  The CD70-CD27 axis in oncology: the new kids on the block.

Authors:  Tal Flieswasser; Astrid Van den Eynde; Jonas Van Audenaerde; Jorrit De Waele; Filip Lardon; Carsten Riether; Hans de Haard; Evelien Smits; Patrick Pauwels; Julie Jacobs
Journal:  J Exp Clin Cancer Res       Date:  2022-01-06

Review 7.  The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps.

Authors:  Silvia Gitto; Ambra Natalini; Fabrizio Antonangeli; Francesca Di Rosa
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561

8.  Evaluation of Safety and Side Effects COVID-19 Vaccine in Cancer Patients Being Treated.

Authors:  Mozaffar Aznab; Maryam Chalehchaleh; Somayeh Dokoshkani; Maryam Rezaei
Journal:  Asian Pac J Cancer Prev       Date:  2022-04-01

9.  Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET).

Authors:  Amy Body; Elizabeth Ahern; Luxi Lal; Karen Gillett; Hesham Abdulla; Stephen Opat; Tracey O'Brien; Peter Downie; Stuart Turville; C Mee Ling Munier; Corey Smith; C Raina MacIntyre; Eva Segelov
Journal:  BMC Infect Dis       Date:  2022-01-20       Impact factor: 3.090

10.  Significant clinical response of advanced colorectal cancer to combination therapy involving capecitabine and adoptive cell transfer therapy: a case report.

Authors:  Shuchun Li; Junjun Ma; Xizhou Hong; Minhua Zheng; Shigenori Goto; Rishu Takimoto; Takashi Kamigaki; Lu Zang
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.